查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854772

病毒載體市場按載體類型、產品類型、治療領域、最終用戶、生產階段和生產規模分類－2025-2032年全球預測

Viral Vectors Market by Vector Type, Application, Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，病毒載體市場規模將達到 56 億美元，複合年成長率為 14.56%。

關鍵市場統計數據
基準年 2024 18.8億美元
預計年份：2025年 21.6億美元
預測年份 2032 56億美元
複合年成長率 (%) 14.56%

本書簡明扼要地介紹了病毒載體生態系統，旨在培養技術、監管和商業性交叉領域的領導者。

病毒載體目前處於前沿生物學和複雜製造過程的交匯點。本導論整合了核心科學模式、關鍵製造曲折點以及將研究成果轉化為臨床應用的轉化路徑。它重點闡述了載體生物學（衣殼選擇、嗜性、有效載荷設計）如何與上游細胞培養、轉染方法和下游純化等製程因素相互作用，從而確定整個專案的可行性和時間安排。

在整個研發生命週期中，監管預期和分析要求日益影響設計選擇。因此，早期關於載體類型、生產平台和品質屬性的決策會層層遞進地影響後續的臨床可比性和商業供應的風險評估。本節將闡述決策者在選擇合作夥伴、投資內部研發能力以及製定臨床開發計劃時必須權衡的關鍵營運和策略因素。其目標是為高階主管、專案負責人和生產規劃人員提供一個統一的思維模型，幫助他們明確科學機會與生產可行性和監管要求之間的平衡。

技術創新、監管演變和供應鏈韌性如何推動病毒載體開發和遞送的根本性轉變

多種因素共同作用，重塑了病毒載體的格局。載體工程技術的進步——包括改進的衣殼設計、新型血清型和最佳化的基因組結構——正在拓展組織靶向性和安全性，從而拓寬治療應用範圍。同時，分析方法的進步，例如次世代定序和高解析度雜質分析，使得對產品進行嚴格的表徵以及建立可靠的製程差異比較策略成為可能。

在生產製造方面，模組化生物製程和一次性使用技術正在加快臨床試驗的周轉速度，並降低早期臨床試驗的資本投入。同時，可擴展層析法化學和替代純化方法的成熟，使製造商能夠應對產量和純度方面長期存在的挑戰。監管機構也不斷調整其預期。他們強調穩健的控制策略、雜質的詳細表徵以及明確的生產變更過渡要求，鼓勵申辦方更早將監管因素納入其研發計劃。

最後，全球供應鏈與地緣政治環境正促使相關人員實現採購多元化、關鍵生產流程在地化，並建立策略供應商關係。這些技術、監管和營運方面的變化正在重新定義可行的商業模式，以及將治療方法從實驗室安全推向臨床的時間表。

評估近期關稅政策對病毒載體生產投入品供應鏈、成本和策略採購的累積影響（至2025年）

近期關稅措施和貿易政策的變化，給病毒載體生產所需的原料、設備和專用耗材的採購成本計算引入了新的變數。其累積影響不僅限於直接的零件成本，還波及採購前置作業時間、供應商談判和庫存策略。依賴進口一次性系統、專用層析法樹脂或專有設備的工廠，可能會面臨更長的認證週期和更高的到岸成本，迫使專案團隊評估供應商冗餘和在地採購方案。

除了直接採購之外，關稅還會影響資本規劃決策。評估新建無塵室、灌裝包裝產能或境內契約製造夥伴關係的公司，現在必須權衡設備進口成本的變化與供應商的供貨情況。這促使企業更加關注模組化和移動式生產方式，以減少對重型機械的依賴，並實現產能的逐步擴張。此外，關稅帶來的波動也凸顯了強力的供應商績效指標、關鍵試劑的雙重採購以及在保存期限和穩定性允許的情況下進行策略性儲備的重要性。

最終，雖然關稅會造成摩擦和成本壓力，但它們也會加速供應鏈的韌性、關鍵供應商的夥伴關係，以及向區域製造佈局的策略轉變，從而平衡風險和營運彈性。

基於對關鍵細分市場的洞察，突顯了技術、臨床和商業性差異化在病毒載體市場中創造策略機會的領域。

透過細分，我們可以揭示載體生物學、應用領域、治療標靶、最終用戶、生產階段和規模等方面的價值和風險所在。依載體類型分類，腺結合病毒、腺病毒、慢病毒和逆轉錄病毒各有其獨特的優缺點。腺相關病毒通常具有較高的安全性和組織嗜性優勢，而AAV2、AAV8和AAV9是常用的血清型，但它們在生物分佈和預存免疫因素方面存在差異。腺病毒具有高載藥量和轉導效率，適用於瞬時表達，而慢病毒和逆轉錄病毒則為持久性、整合性方法（例如體外細胞療法）奠定了基礎。這些差異要求我們制定客製化的生產和分析策略，以使分子特性與治療目標相符。

應用細分突顯了不同的研發和生產路徑。細胞療法、基因療法、研究和疫苗應用各自擁有獨特的流程和監管要求。細胞療法需要針對特定療法（例如 CAR-T 細胞、樹突狀細胞和 TCR-T 細胞）進行載體給藥、療效和安全性測試。基因療法分為體外和體內兩種方法，每種方法對載體純度和生物分佈的要求各不相同。研究應用涵蓋基礎研究和臨床前研究，因此需要靈活的小規模生產和快速的周轉時間。同時，預防性和治療性疫苗計畫優先考慮可擴展、經濟高效的生產和批次可追溯性。

優先排序在心血管、感染疾病、神經病學、腫瘤學和罕見病等治療領域進一步細化：心血管項目分為專注於冠狀動脈疾病和周邊血管疾病的項目，這帶來了不同的給藥挑戰；感染疾病分為針對細菌和病毒的項目，這會影響抗原設計和免疫抗原性管理；神經學計畫分為神經退化性疾病，這會影響給藥途徑和安全性監測；罕見疾病通常是單一疾病，需要高度個人化的產品策略和靈活的生產方式來支持小批量、多品種的生產。

最終用戶——生物製藥公司、醫院和診所以及研究機構——各自有著不同的需求和對服務的期望。生物製藥公司通常需要整合的開發和商業化規模解決方案；醫院和診所優先考慮注射劑型、低溫運輸物流和即時檢測能力；而研發機構則優先考慮調查方法的快速獲取和靈活性。將生產階段分類為下游和上游後發現，對過濾、製劑、純化、細胞擴增、收穫和轉染的投資對營運影響最大。雖然下游純化（包括層析法和超速離心）仍然是純度和產量方面的一個瓶頸，但提高上游細胞擴增和轉染效率可以直接提高載體的生產力。臨床試驗需要靈活的、分階段的生產模式，涵蓋I期、II期和III期，而商業性的大規模生產則強調可重複性、成本最佳化和長期供應協議。

綜合來看，這些細分層提供了一個多維地圖，可以根據治療方式、目標人口和商業化途徑，優先考慮技術投資、夥伴關係模式和製造佈局。

影響美洲、歐洲、中東和非洲以及亞太地區市場准入、製造策略和夥伴關係模式的區域動態

區域因素對病毒載體開發和部署的策略選擇有顯著影響。在美洲，成熟的生物技術叢集和先進的製造網路支持快速轉化途徑和對接專業合約研發生產機構（CDMO），但專案團隊也必須應對影響商業化策略的區域監管預期和報銷環境。在歐洲、中東和非洲，監管協調工作和各國醫療保健體系的差異既為跨國合作創造了機遇，也增加了臨床試驗設計的複雜性。在亞太地區，GMP生產能力的快速擴張、不斷壯大的本地科研人才庫以及對本土生物製造的政策獎勵正在加速產能成長，但申辦方必須仔細評估這些因素對區域供應可靠性、本地化程度和知識產權的影響。

臨床試驗招募動態、目標適應症盛行率和支付方評估標準在不同地區差異顯著，這影響著關鍵性試驗的進行地點和打入市場策略的建構。製造地的選擇同樣受到區域成本結構、人才供應和與患者群體接近性等因素的影響。鑑於這些差異，企業正擴大採用混合模式，將區域研發中心與分散式製造地相結合，以平衡成本、監管合規性和患者用藥時間。最終，區域策略必須與產品概況、臨床設計和商業准入計畫緊密結合，以確保從研發到分銷的順利過渡。

透過對病毒載體生態系統中競爭對手和合作夥伴的分析，重點關注其能力叢集、夥伴關係模式和策略重點。

病毒載體領域的開發人員可根據其核心競爭力進行分類，包括專注於平台工程和衣殼發現的公司、專注於可擴展GMP生產的供應商以及提供端到端開發支援的整合商。平台創新者優先考慮深度分子工程、進階分析、血清型設計和免疫逃脫策略的智慧財產權組合，通常支援跨多個治療領域的臨床計畫。生產專家則強調製程穩健性、高產量上游平台以及能夠解決長期瓶頸的下游純化技術。整合商和CDMO整合了這些能力，提供模組化服務，使申辦者能夠以可預測的時間表和監管支援加速臨床供應。

策略夥伴關係日益普遍，技術授權者與合約研發生產機構 (CDMO) 和學術轉化研究團隊合作，以降低早期專案的風險並擴大成功候選藥物的規模。各公司之間的競爭還包括服務範圍、地域覆蓋以及管理複雜對比試驗的能力。對於尋求從臨床供應過渡到商業供應的公司而言，在分析開發、數位化批記錄和品質自動化方面的投資是勝利的關鍵。對於評估合作夥伴的高階主管而言，在品質文化、資料透明度和供應連續性應急計畫方面的一致性是衡量長期可靠性的最重要指標。

為確保病毒載體專案的持續開發、監管合規和商業性化準備，產業領導者應立即實施以下切實可行的建議

優先考慮早期整合規劃，將衣殼選擇、有效載荷設計和生產策略與監管要求聯繫起來。讓監管和品質專家參與早期專案決策，可以降低後期出現意外情況的風險，並在需要進行製程變更時簡化可比性。同時，投資早期分析深度，以建立可靠的效力和雜質檢測方法，從而支持新藥臨床試驗申請（IND）和未來的生產轉移。

透過關鍵耗材的雙重採購和確定區域供應商來縮短前置作業時間，從而增強供應鏈韌性。在可行的情況下，採用模組化或一次性使用的生產元件，以加快臨床供應，而無需大量資本投入。作為長期策略，評估混合生產模式，將區域臨床供應中心與集中式商業能力結合，以最佳化成本並確保患者獲得所需藥品。

我們協商的夥伴關係協議包含明確的品質指標、資料存取條款以及應對供應中斷的緊急條款。最後，透過及早與市場進入和醫學事務部門接洽，明確證據產生需求和患者准入途徑，我們將商業計劃與臨床開發相協調，確保從監管部門核准到臨床應用的順利過渡。

在病毒載體領域，為獲得可靠、可重複、決策層面的見解而採用的調查方法和途徑

本研究整合了來自行業專家的訪談、監管指南的定性分析以及技術文獻，以三角驗證病毒載體開發對營運和策略的影響。一級資訊來源包括製程開發、分析科學、品質和商業部門的專家，從而提供了對製程瓶頸、技術應用和夥伴關係行為的綜合視角。二級資訊來源則利用同儕審查的研究、監管指南文件和公開資訊來支持技術說明並檢驗觀察到的行業趨勢。

透過定性洞察和技術可行性的交叉檢驗，例如將上游產量與說明精煉限制條件檢驗，以評估實際製程產能，從而實現分析的嚴謹性。調查方法優先考慮證據來源的透明度，明確區分基於專家判斷的結論和已公開的文件。文中貫穿對局限性和敏感性的討論，以支持負責任的解讀，並在必要時指導後續原始數據的收集。

綜合各項結論，重申策略重點，並聚焦在對媒介傳播成功至關重要的操作槓桿。

一個根本性的教訓是，僅靠科學進步並不能保證專案成功。成功的病毒載體專案取決於載體選擇和有效載荷設計與可擴展生產流程的匹配，早期引入嚴謹的分析方法，以及建立能夠提供技術支援和穩定供應的夥伴關係關係。採用模組化生產方法、投資深入的分析研發並積極管理供應商風險的機構，更有可能將前景廣闊的生物科學成果轉化為可靠的臨床和商業供應。

隨著生態系的成熟，領導者應將能力建構視為策略重點，而非事後考量。這意味著要投入資源用於品質體系、流程表徵和策略供應商關係，同時保持靈活性，以適應不斷變化的監管預期和地緣政治貿易動態。簡而言之，創造永續價值的關鍵在於平衡科學創新與營運紀律。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 改進腺結合病毒衣殼以實現靶向體內基因遞送
  • 擴展連續生物製程平台以提高病毒載體生產能力
  • 將一次性生物反應器技術整合到可擴展的慢病毒載體生產系統中
  • 一種用於病毒載體基因表現中可調控啟動子的新型合成生物學方法
  • 合約生產商與生技公司之間的策略合作加速了病毒載體供應鏈的韌性
  • 為實現病毒載體療法的全球臨床試驗核准，監管協調工作正在進行中。
  • 開發編碼mRNA的病毒載體，以快速應對新興感染疾病疫情
  • 在病毒載體純化工作流程中實施高階分析和人工智慧驅動的流程監控

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按載體類型分類的病毒載體市場

  • 腺結合病毒
    • AAV2
    • AAV8
    • AAV9
  • 腺病毒
  • 慢病毒
  • 逆轉錄病毒

第9章 按應用分類的病毒載體市場

  • 細胞療法
    • Car T
    • 樹突狀細胞
    • TCR T
  • 基因治療
    • 體外
    • In vivo
  • 研究
    • 基礎研究
    • 臨床前研究
  • 疫苗
    • 預防
    • 治療

第10章 按治療領域分類的病毒載體市場

  • 心血管疾病
    • 冠狀動脈
    • 周邊血管
  • 感染疾病
    • 細菌
    • 病毒
  • 神經系統疾病
    • 神經退化
    • 神經發育
  • 腫瘤學
    • 血液學
    • 固態腫瘤
  • 罕見疾病
    • 單基因

第11章 病毒載體市場（依最終用戶分類）

  • 生物製藥公司
  • 醫院和診所
  • 研究所

第12章 病毒載體市場依生產階段分類

  • 下游
    • 濾
    • 處方
    • 純化
      • 層析法
      • 超速離心
  • 上游
    • 細胞增殖
    • 收成
    • 轉染

第13章 病毒載體市場（依生產規模分類）

  • 臨床
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的
    • 全面

第14章 病毒載體市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 病毒載體市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國病毒載體市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Lonza Group AG
    • Merck KGaA
    • Catalent Inc.
    • WuXi AppTec Co., Ltd.
    • Novasep Holding SAS
    • Oxford BioMedica plc
    • AGC Biologics Inc.
    • Cobra Biologics Ltd.
    • Viralgen SL
Product Code: MRR-957C47F9405B

The Viral Vectors Market is projected to grow by USD 5.60 billion at a CAGR of 14.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.88 billion
Estimated Year [2025] USD 2.16 billion
Forecast Year [2032] USD 5.60 billion
CAGR (%) 14.56%

A concise orientation to the viral vectors ecosystem that prepares leaders for technical, regulatory, and commercial intersections

Viral vectors now sit at the intersection of cutting-edge biology and complex manufacturing. This introduction synthesizes the core scientific modalities, the critical manufacturing inflection points, and the translational pathways that convert research signals into clinical programs. It focuses on how vector biology-capsid selection, tropism, and payload design-interacts with process considerations such as upstream cell culture, transfection methods, and downstream purification to determine overall program feasibility and timelines.

Across the development lifecycle, regulatory expectations and analytical requirements increasingly shape design choices. As a result, early decisions about vector type, production platform, and quality attributes cascade into downstream risk profiles for clinical comparability and commercial supply. Accordingly, this section frames the primary operational and strategic tradeoffs decision-makers must weigh when selecting partners, investing in in-house capabilities, or designing clinical development plans. The aim is to equip executives, program leads, and manufacturing planners with a cohesive mental model that clarifies where scientific opportunity aligns with manufacturing practicality and regulatory acceptability.

How technological innovations, regulatory evolution, and supply chain resilience are driving foundational shifts in viral vector development and delivery

The landscape for viral vectors is being reshaped by several converging forces. Advances in vector engineering-improved capsid design, novel serotypes, and optimized genome constructs-are expanding tissue targeting and safety profiles, which in turn broaden therapeutic applicability. Parallel progress in analytical methods, including next-generation sequencing and high-resolution impurity profiling, has tightened product characterization and enabled more confident comparability strategies between process variants.

On the manufacturing front, modular bioprocessing and single-use technologies are driving faster campaign turnarounds and lower capital exposure for early clinical work. At the same time, the maturation of scalable chromatography chemistries and alternative purification approaches is enabling manufacturers to tackle persistent yield and purity challenges. Regulatory bodies are also evolving their expectations; regulators are emphasizing robust control strategies, detailed characterization of impurities, and clearer bridging requirements for manufacturing changes, prompting sponsors to integrate regulatory thinking earlier into development plans.

Finally, the global supply chain and geopolitical context are encouraging stakeholders to diversify sourcing, localize critical production steps, and cultivate strategic supplier relationships. Together, these technological, regulatory, and operational shifts are redefining viable commercial models and the timelines for safely moving therapies from lab to clinic.

Assessment of cumulative effects from recent tariff policies on supply chains, costs, and strategic sourcing for viral vector production inputs in 2025

Recent tariff measures and trade policy shifts have introduced new variables into the sourcing calculus for raw materials, equipment, and specialized consumables used in viral vector manufacturing. The cumulative impact is felt not only in direct component costs but also in procurement lead times, supplier negotiations, and inventory strategies. Facilities that rely on imported single-use systems, specialized chromatography resins, or proprietary equipment may experience extended qualification timelines and higher landed costs, prompting program teams to reassess supplier redundancy and localized sourcing options.

Beyond direct procurement, tariffs can influence capital planning decisions. Organizations evaluating new cleanroom builds, fill-finish capacity, or onshore contract manufacturing partnerships must now weigh altered equipment import economics and vendor availability. This has sharpened interest in modular and mobile manufacturing approaches that reduce heavy equipment dependence and allow incremental capacity expansion. Furthermore, tariff-driven variability has highlighted the importance of robust supplier performance metrics, dual sourcing for critical reagents, and strategic stockpiling where shelf life and stability allow.

Ultimately, while tariffs add friction and cost pressure, they also accelerate strategic shifts toward supply chain resilience, critical supplier partnerships, and regional manufacturing footprints that balance risk with operational flexibility.

Key segmentation-driven insights that clarify where technical, clinical, and commercial differentiation creates strategic opportunity across the viral vectors market

Segmentation illuminates where value and risk concentrate across vector biology, application areas, therapeutic targets, end users, production stages, and scale. When categorized by vector type, Adeno Associated Virus, Adenovirus, Lentivirus, and Retrovirus each present distinct tradeoffs: Adeno Associated Virus generally offers strong safety and tissue tropism advantages, with AAV2, AAV8, and AAV9 representing commonly referenced serotypes that differ in biodistribution and preexisting immunity considerations; Adenovirus provides high payload capacity and transduction efficiency for transient expression; Lentivirus and Retrovirus are foundational for durable, integrating approaches such as ex vivo cell therapies. These differences demand tailored manufacturing and analytical strategies that match molecular attributes to therapeutic intent.

Application segmentation underscores divergent development and manufacturing pathways. Cell Therapy, Gene Therapy, Research, and Vaccine applications have unique process and regulatory footprints. Within Cell Therapy, CAR T, Dendritic, and TCR T modalities pose specific vector dosing, potency assay, and safety testing needs. Gene Therapy divides into Ex Vivo and In Vivo approaches, each with differing vector purity and biodistribution requirements. Research applications span Basic Research and Preclinical Research, driving demand for flexible small-scale production and rapid turnaround, while Vaccine programs-both Prophylactic and Therapeutic-prioritize scalable, cost-efficient manufacturing and batch traceability.

Therapeutic area segmentation-Cardiovascular Disorders, Infectious Disease, Neurological Disorders, Oncology, and Rare Diseases-further refines prioritization. Cardiovascular programs split into coronary and peripheral vascular focuses with distinct delivery challenges; Infectious Disease divides into bacterial and viral targets that impact antigen design and immunogenicity management; Neurological Disorders separate into neurodegenerative and neurodevelopmental conditions that influence administration routes and safety monitoring; Oncology programs bifurcate into hematological and solid tumor strategies with differing cell targeting and tumor microenvironment considerations; Rare Diseases, often monogenic, demand highly individualized product strategies and flexible manufacturing capable of low-volume, high-complexity production.

End users-Biopharma Companies, Hospitals And Clinics, and Research Institutes-drive different demand profiles and service expectations. Biopharma companies often require integrated development and commercial scale solutions, hospitals and clinics emphasize parenteral formulation, cold chain logistics, and point-of-care readiness, while research institutes prioritize rapid access and methodological flexibility. Production stage segmentation between Downstream and Upstream highlights where investment in filtration, formulation, purification and cell expansion, harvesting, and transfection deliver the greatest operational leverage. Downstream purification, including chromatography and ultracentrifugation, remains a persistent bottleneck for purity and yield, whereas upstream improvements in cell expansion and transfection efficiency directly enhance vector productivity. Finally, production scale segmentation-Clinical and Commercial-reflects different operational cadences: clinical work requires nimble phase-specific manufacturing across Phase I, Phase II, and Phase III, while commercial full-scale operations emphasize reproducibility, cost of goods optimization, and long-term supply agreements.

Taken together, these segmentation layers provide a multidimensional map for prioritizing technology investments, partnership models, and manufacturing footprints based on therapeutic modality, target population, and commercialization pathway.

Regional dynamics shaping access, manufacturing strategy, and partnership models across the Americas, EMEA, and Asia-Pacific jurisdictions

Regional factors strongly influence strategic choices for viral vector development and deployment. In the Americas, established biotech clusters and advanced manufacturing networks support rapid translational pathways and access to specialized CDMOs, but program teams must also navigate regional regulatory expectations and reimbursement landscapes that affect commercialization strategies. In Europe, Middle East & Africa, regulatory harmonization efforts and diverse national health systems create both opportunities for cross-border collaboration and complexity for clinical trial design; here, partnerships with established local manufacturers and academic centers can streamline patient access while aligning to regional compliance frameworks. In the Asia-Pacific region, rapid expansion of GMP capacity, growing local scientific talent pools, and policy incentives for domestic biomanufacturing are accelerating capacity growth, though sponsors must carefully assess regional supply reliability and the implications of local content and intellectual property considerations.

Across these regions, clinical trial recruitment dynamics, prevalence of target indications, and payer evaluation criteria differ significantly, which informs where to site pivotal studies and how to structure market access strategies. Manufacturing location decisions are similarly sensitive to regional cost structures, talent availability, and proximity to patient populations. Given these variances, companies are increasingly adopting hybrid models that pair regional development hubs with distributed manufacturing to balance cost, regulatory alignment, and time to patient. Ultimately, regional strategy must be tightly integrated with product profiling, clinical design, and commercial access planning to ensure successful translation from development to widespread use.

Competitive and collaborative company insights that highlight capability clusters, partnership archetypes, and strategic priorities in the viral vectors ecosystem

Leading organizations in the viral vector space can be grouped by core capabilities: those focused on platform engineering and capsid discovery, providers specializing in scalable GMP manufacturing, and integrators offering end-to-end development support. Platform innovators prioritize deep molecular engineering, advanced analytics, and IP portfolios around serotype design and immune evasion strategies, typically supporting multiple clinical programs across therapeutic areas. Manufacturing specialists emphasize process robustness, high-yield upstream platforms, and downstream purification technologies that address persistent bottlenecks. Integrators and CDMOs bridge these capabilities, offering modular services that allow sponsors to accelerate clinical supply with predictable timelines and regulatory support.

Strategic partnerships are increasingly common, with technology licensors working alongside CDMOs and academic translational groups to de-risk early programs and to scale successful candidates. Companies are also competing on service breadth, geographic footprint, and the ability to manage complex comparability exercises. Investment in analytical development, digital batch records, and quality automation is a differentiator for organizations aiming to move from clinical to commercial supply. For executives assessing partners, alignment on quality culture, data transparency, and contingency planning for supply continuity are the most important indicators of long-term reliability.

Actionable recommendations that industry leaders should deploy now to secure development continuity, regulatory alignment, and commercial readiness for viral vector programs

Prioritize integrated early-stage planning that ties capsid selection, payload design, and manufacturing strategy to regulatory expectations. Embedding regulatory and quality experts into early program decisions reduces the risk of late-stage surprises and simplifies comparability when process changes become necessary. Concurrently, invest in analytical depth early to establish robust potency and impurity assays that will support both IND filings and future manufacturing transfers.

Strengthen supply chain resilience through dual sourcing of critical consumables and by qualifying regional suppliers to shorten lead times. Where feasible, adopt modular or single-use manufacturing elements to accelerate clinical supply without heavy capital commitments. For longer-term strategies, assess hybrid manufacturing footprints that combine regional clinical supply hubs with centralized commercial capacity to optimize cost and ensure patient access.

Negotiate partnership agreements that include clear quality metrics, data access provisions, and contingency clauses for supply disruptions. Finally, align commercial planning with clinical development by engaging market access and medical affairs early to define evidence generation needs and patient access pathways, thereby smoothing the transition from regulatory approval to real-world use.

Research approach and methodologies employed to produce robust, reproducible, and decision-grade insights across the viral vectors domain

This research synthesizes evidence from primary interviews with industry experts, qualitative analyses of regulatory guidance, and technical literature to triangulate the operational and strategic implications for viral vector development. Primary sources include subject matter experts across process development, analytical science, quality, and commercial functions, providing a composite view of process bottlenecks, technology adoption, and partnership behaviors. Secondary inputs draw on peer-reviewed studies, regulatory guidance documents, and public disclosures to ground technical descriptions and to validate observed industry trends.

Analytical rigor is achieved through cross-validation of qualitative insights with technical feasibility checks, for example correlating described upstream yields with downstream purification constraints to assess realistic process throughput. The methodology prioritizes transparency about evidence provenance, explicitly flagging where conclusions derive from consensus expert judgment versus established public documentation. Limitations and sensitivity considerations are noted throughout to support responsible interpretation and to guide areas for additional primary data collection where required.

Concluding synthesis that reaffirms strategic priorities and highlights the most consequential operational levers for viral vector success

The fundamental takeaway is that scientific advances alone will not guarantee program success; operational execution, regulatory foresight, and supply chain design are equally determinative. Success in viral vector programs depends on aligning vector selection and payload design with scalable manufacturing processes, embedding analytical rigor early, and structuring partnerships that offer both technical capability and supply continuity. Organizations that adopt modular manufacturing approaches, invest in deep analytical development, and proactively manage supplier risk will be better positioned to translate promising biological science into reliable clinical and commercial supply.

As the ecosystem matures, leaders should treat capability building as a strategic priority rather than an operational afterthought. This means committing resources to quality systems, process characterization, and strategic supplier relationships while maintaining flexibility to adapt to evolving regulatory expectations and geopolitical trade dynamics. In short, the path to durable value lies in marrying scientific innovation with disciplined operational practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in engineered adeno-associated virus capsids for targeted in vivo gene delivery
  • 5.2. Expansion of continuous bioprocessing platforms to increase viral vector manufacturing capacity
  • 5.3. Integration of single-use bioreactor technologies in scalable lentiviral vector production systems
  • 5.4. Emerging synthetic biology approaches for tunable promoter control in viral vector gene expression
  • 5.5. Strategic collaborations between CMOs and biotech firms to accelerate viral vector supply chain resilience
  • 5.6. Regulatory harmonization initiatives addressing global clinical trial approval for viral vector therapies
  • 5.7. Development of mRNA-encoding viral vectors for rapid vaccine response to novel infectious disease outbreaks
  • 5.8. Implementation of advanced analytics and AI-driven process monitoring in viral vector purification workflows

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Vectors Market, by Vector Type

  • 8.1. Adeno Associated Virus
    • 8.1.1. AAV2
    • 8.1.2. AAV8
    • 8.1.3. AAV9
  • 8.2. Adenovirus
  • 8.3. Lentivirus
  • 8.4. Retrovirus

9. Viral Vectors Market, by Application

  • 9.1. Cell Therapy
    • 9.1.1. Car T
    • 9.1.2. Dendritic
    • 9.1.3. TCR T
  • 9.2. Gene Therapy
    • 9.2.1. Ex Vivo
    • 9.2.2. In Vivo
  • 9.3. Research
    • 9.3.1. Basic Research
    • 9.3.2. Preclinical Research
  • 9.4. Vaccine
    • 9.4.1. Prophylactic
    • 9.4.2. Therapeutic

10. Viral Vectors Market, by Therapeutic Area

  • 10.1. Cardiovascular Disorders
    • 10.1.1. Coronary
    • 10.1.2. Peripheral Vascular
  • 10.2. Infectious Disease
    • 10.2.1. Bacterial
    • 10.2.2. Viral
  • 10.3. Neurological Disorders
    • 10.3.1. Neurodegenerative
    • 10.3.2. Neurodevelopmental
  • 10.4. Oncology
    • 10.4.1. Hematological
    • 10.4.2. Solid Tumor
  • 10.5. Rare Diseases
    • 10.5.1. Monogenic

11. Viral Vectors Market, by End User

  • 11.1. Biopharma Companies
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. Viral Vectors Market, by Production Stage

  • 12.1. Downstream
    • 12.1.1. Filtration
    • 12.1.2. Formulation
    • 12.1.3. Purification
      • 12.1.3.1. Chromatography
      • 12.1.3.2. Ultracentrifugation
  • 12.2. Upstream
    • 12.2.1. Cell Expansion
    • 12.2.2. Harvesting
    • 12.2.3. Transfection

13. Viral Vectors Market, by Production Scale

  • 13.1. Clinical
    • 13.1.1. Phase I
    • 13.1.2. Phase II
    • 13.1.3. Phase III
  • 13.2. Commercial
    • 13.2.1. Full Scale

14. Viral Vectors Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Viral Vectors Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Viral Vectors Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. Lonza Group AG
    • 17.3.3. Merck KGaA
    • 17.3.4. Catalent Inc.
    • 17.3.5. WuXi AppTec Co., Ltd.
    • 17.3.6. Novasep Holding SAS
    • 17.3.7. Oxford BioMedica plc
    • 17.3.8. AGC Biologics Inc.
    • 17.3.9. Cobra Biologics Ltd.
    • 17.3.10. Viralgen S.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 329. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 330. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 334. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 335. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 336. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 337. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 340. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 341. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)

TABLE 346.